V1rg10 inhibitors are a collection of chemicals that directly or indirectly suppress the activity of the V1rg10 receptor, a component of the sensory machinery in the vomeronasal organ. These inhibitors act through various molecular mechanisms to dampen the receptor's ability to detect and respond to specific chemical stimuli. For instance, some inhibitors act by blocking ion channels that are vital for the activation of the neurons expressing V1rg10, thereby preventing the initial electrical responses that these ligand-gated channels typically mediate upon activation by their ligands. Others interfere with intracellular signaling cascades that are essential for translating the receptor's activation into a cellular response, such as those involving second messengers like inositol triphosphate (IP3) or cyclic GMP.
The inhibition of these pathways can lead to a reduced activation or sensitization of V1rg10, ultimately suppressing the receptor's normal function. Some of the inhibitors block specific enzymes like nitric oxide synthase or CaM kinase II, which play roles in modulating the receptor's sensitivity or the strength of its signaling. Others obstruct neurotransmitter receptors that regulate the release of molecules that can either potentiate or inhibit V1rg10 signaling, thereby indirectly influencing the receptor's activity. By affecting these various elements of the signaling network, V1rg10 inhibitors can decrease the receptor's ability to contribute to the sensory processing of chemical cues that are critical for the organism's interaction with its environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(+)-Bicuculline | 485-49-4 | sc-202498 sc-202498A | 50 mg 250 mg | $82.00 $281.00 | ||
Inhibits GABA_A receptors, which can lead to increased excitability of neurons in the accessory olfactory bulb, thereby reducing the sensitivity of V1rg10 to its ligands. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Blocks CaM kinase II, which can lead to reduced phosphorylation of proteins within the V1rg10 signaling cascade, resulting in inhibited receptor signaling. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
Inhibits nitric oxide synthase, which can lead to reduced nitric oxide-facilitated modulation of V1rg10 receptor function. | ||||||
Methyllycaconitine citrate | 112825-05-5 | sc-253043 sc-253043A | 5 mg 25 mg | $119.00 $406.00 | 2 | |
Inhibits neuronal nicotinic acetylcholine receptors, which can lead to decreased cholinergic modulation of V1rg10 receptor signaling. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Antagonizes multiple neurotransmitter receptors, including serotonergic and muscarinic receptors, leading to reduced modulation of V1rg10 receptor function. | ||||||
ODQ | 41443-28-1 | sc-200325 sc-200325A | 10 mg 50 mg | $78.00 $222.00 | 13 | |
Inhibits soluble guanylate cyclase, leading to decreased cGMP production, which is important for the signaling of V1rg10 receptors. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
Blocks ryanodine receptors, which can lead to decreased intracellular calcium release, crucial for V1rg10 signaling. | ||||||